Partial
Needs Review
Patient Risk:
Moderate
Summary
Some medication-use claims (asthma/COPD) are directionally consistent with the label conceptually, but the response mainly discusses coupons/discounts/PAPs and provides no label-supported basis for these non-label topics. Due to lack of label support for these claims, overall alignment is partial.
Category Scores
Accurate Statements
Advair is used for asthma treatment.
Label indicates ADVAIR DISKUS is indicated for twice-daily treatment of asthma (Section 1). Label indicates ADVAIR HFA is indicated for treatment of asthma in adult and adolescent patients aged 12 years and older (Section 1).
Advair is used for COPD treatment.
Label indicates ADVAIR DISKUS 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in COPD (Section 1).
Unsupported Statements
GlaxoSmithKline, the manufacturer of Advair, occasionally offers coupons and rebates on its official website.
No coupon/rebate statements are present in the provided FDA label excerpts; therefore unsupported by the supplied prescribing information.
GlaxoSmithKline offers coupons and rebates on their official website or through their patient assistance program for Advair.
No coupon/rebate or manufacturer patient assistance program details are present in the provided FDA label excerpts; therefore unsupported.
Advair coupons may have eligibility requirements such as income limits.
No eligibility requirements (income limits) are described in the provided FDA label excerpts; unsupported.
Advair coupons may have eligibility requirements such as medical condition requirements.
No eligibility requirements are described in the provided FDA label excerpts; unsupported.
Patient assistance programs (PAPs) are available for Advair.
No statements about PAP availability are present in the provided FDA label excerpts; unsupported.
Patient assistance programs for Advair can help eligible patients receive discounted or free medication.
No statements about PAP benefits/discounts/free medication are present in the provided FDA label excerpts; unsupported.
Discount card providers such as GoodRx offer coupons and discounts on Advair.
No statements about third-party discount card providers or coupons are present in the provided FDA label excerpts; unsupported.
Discount card providers such as RxSaver offer coupons and discounts on Advair.
No statements about third-party discount card providers or coupons are present in the provided FDA label excerpts; unsupported.
Coupons and discounts on Advair from discount card providers typically require a prescription.
No statements about prescription requirement for coupons/discount programs are present in the provided FDA label excerpts; unsupported.
Coupons and discounts on Advair from discount card providers may have specific requirements or limitations.
No statements about coupon/discount requirements or limitations are present in the provided FDA label excerpts; unsupported.
Local pharmacies, advocacy groups, or community organizations may offer Advair coupons or discounts.
No statements about coupons/discounts from pharmacies/advocacy/community organizations are present in the provided FDA label excerpts; unsupported.
Some online coupons or discount offers for Advair may be expired or no longer valid.
No statements about validity/expiration of coupons/discount offers are present in the provided FDA label excerpts; unsupported.
Some resources that offer Advair discounts may require registration, validation, or specific requirements to access the discounts.
No statements about registration/validation requirements for discount offers are present in the provided FDA label excerpts; unsupported.
Advair coupon authenticity and validity should be verified before using them.
No statements about verifying coupon authenticity/validity are present in the provided FDA label excerpts; unsupported.
Contradictions
AI Statement
Advair is used for COPD treatment.
Label Reference
Label indicates COPD indication is specifically for ADVAIR DISKUS 250/50 maintenance treatment of airflow obstruction in COPD (Section 1). The claim does not specify product/strength; not directly contradicted but is imprecise relative to the label excerpt.
Important Omissions
For the COPD claim, the label excerpt specifies ADVAIR DISKUS 250/50 indicated for COPD; the response does not specify the product/strength and may therefore omit material labeling specificity.
Importance:
Moderate
No label-based limitations of use were mentioned (e.g., ADVAIR is not indicated for relief of acute bronchospasm/rescue therapy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The non-label coupon/PAP guidance is not supported by the provided prescribing information; additionally, omission of the label limitation that ADVAIR is not for acute bronchospasm/rescue therapy could indirectly contribute to misuse if relied upon without label-consistent counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Review
Primary Issue
Major portions of the response (coupons, rebates, eligibility, PAPs, and third-party discount programs) are not supported by the provided FDA label excerpts; only general asthma/COPD indication statements align directionally with Section 1.
Suggested Improvement
Restrict the response to FDA-label-supported information provided in the label excerpts (e.g., indications and limitations of use such as not being for rescue therapy). Remove or clearly separate non-label discount/coupon/PAP claims, since no label support is provided.